Welcome to our dedicated page for Sinovac Biotech SEC filings (Ticker: SVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sinovac Biotech Ltd. filings document the company’s foreign private issuer reporting for a China-based vaccine developer, including Form 20-F annual reporting and Form 6-K current reports. The disclosures cover vaccine operations, consolidated financial statements, interim results, product portfolio context and pipeline categories such as combination vaccines, recombinant protein vaccines, mRNA technologies and antibodies.
Recent filings also record auditor engagement and annual-report correction matters, Nasdaq listing-compliance notices tied to filing deadlines, and board governance actions, including director independence, committee appointments and proceedings over board composition. These filings frame Sinovac’s capital-market reporting, governance controls and regulatory status as a Nasdaq issuer.
Vivo Capital VIII, LLC and Vivo Capital IX, LLC filed Amendment No. 6 to their Schedule 13D regarding Sinovac Biotech Ltd. (NASDAQ: SVA) on 11 July 2025. The filing updates share ownership and details an ongoing proxy and litigation battle over control of Sinovac’s board.
Ownership: Vivo Capital VIII reports 1,361,236 common shares (1.9%); Vivo Capital IX reports 4,541,764 common shares (6.3%), based on 71,860,702 shares outstanding, for a combined 8.2% economic interest. Both entities have shared voting and dispositive power over their respective holdings.
Purpose of transaction: The amendment narrates events surrounding a Special Meeting called for 8 July 2025. Sinovac sought a court injunction to exclude Vivo and another investor from voting. Vivo opposed the injunction; the Eastern Caribbean Court of Appeal stayed enforcement on 8 July, enabling Vivo to vote its shares by proxy in favor of SAIF’s director slate (including Mr. Shan Fu). Sinovac disclosed on 10 July 2025 that the SAIF-backed slate was elected and Mr. Fu joined the board.
Vivo states it will continue to engage with other shareholders and pursue actions under Item 4 of Schedule 13D, such as influencing board composition, dividend policy, auditor replacement, SEC filing compliance, and a potential NASDAQ relisting. Vivo also references multiple legal proceedings, including a 30 June 2025 U.S. District Court injunction compelling disclosure from shareholders linked to Sinovac’s chairman.
Exhibits: Two press releases (2 July 2025 and 9 July 2025) describing the legal developments are incorporated by reference.
Implications for investors: The filing confirms an activist position totaling 8.2% of Sinovac’s equity and outlines continuing efforts to reshape governance. While successful in electing a new board slate, persistent litigation indicates ongoing uncertainty around corporate control and future strategic direction.
Schedule 13D/A (Amendment No. 5) – Sinovac Biotech Ltd. (SVA) details the current ownership position and voting intentions of 1Globe Capital LLC and its affiliate 1Globe Biomedical (Hong Kong) Co. Ltd.
Ownership snapshot:
- Total beneficial ownership: 18,515,315 common shares, equal to 32.3 % of the outstanding shares (based on the 57.28 million share count from Sinovac’s 2018 20-F).
- Sole voting / dispositive power: 6,812,855 shares.
- Shared voting / dispositive power: 11,702,460 shares (primarily via CDH Utopia Ltd. and related parties).
Proxy contest stance: On 27 June 2025, Dr. Chiang Li (chairman of Sinovac and of both reporting entities) cast his 6.81 million directly-held shares “AGAINST” two proposals to (1) remove the current board (other than Dr. Li) and (2) install a new slate nominated by shareholder SAIF. 1Globe instructed affiliates to vote a further 11.7 million shares against both proposals, aligning roughly one-third of all votes with the incumbent board ahead of the 8 July 2025 special meeting.
Litigation & share-count dispute: Ownership percentages exclude “Exchange Shares” and the “Disputed PIPE” securities issued after May 2018, whose validity is being litigated. The reporting persons, alongside OrbiMed, are parties to multiple suits related to these issuances and prior corporate actions.
Governance implications: 1Globe’s 32 % block makes it difficult for dissident shareholders to secure a majority, increasing the probability that the existing board composition is maintained. Nevertheless, continuing legal challenges over share validity and control keep governance risk elevated and could influence future dilution, corporate actions, and strategic direction.